Comparing NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen for advanced pancreatic adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single‑center, open‑label, randomized Phase 2 trial that assigns previously untreated adults with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma to receive either NALIRIFOX or a modified gemcitabine/nab‑paclitaxel/cisplatin regimen. Patients must have histologic or cytologic confirmation and measurable disease per RECIST 1.1. The trial follows standard chemotherapy dosing schedules and monitors objective response, progression‑free survival, overall survival, and safety. Findings will be compared to historical outcomes for established regimens such as FOLFIRINOX and gemcitabine‑based combinations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged ≥18 years
* For females of reproductive potential: use of highly effective contraception for at least 1 month before screening and agreement to use such a method during study participation and for an additional 9 months after the end of the last dose of study medication administration
* Female patients including WOCBP must test negative for pregnancy at the time of screening based on a urine or serum pregnancy test.
* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner during the study and for 4 months after the last dose of study medication.
* Histologically or cytologically confirmed locally advanced or metastatic PDAC that has not been previously treated
* Radiographically confirmed measurable (per RECIST 1.1) locally advanced or metastatic PDAC per the National Comprehensive Cancer Network (NCCN) definition.
* Inoperable status due to the presence of locally advanced, unresectable disease with or metastases.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Hematological, biochemical, and organ function inclusion criteria:

  * Absolute neutrophil count (ANC) ≥1500/mm3 without the use of hemopoietic growth factors within 7 days before treatment
  * Platelet count ≥100,000/mm3.
  * International normalized ratio (INR) \<1.5 unless the patient is receiving anticoagulation therapy, in which case a therapeutic INR is acceptable. Anticoagulation therapy with low-molecular weight heparin or warfarin, whether medically indicated, is permitted.
  * Adequate renal function, as evidenced by serum/plasma creatinine level \<1.6 mg/dL

Exclusion Criteria:

* Pregnancy or lactation
* Treatment with another investigational drug or other intervention within 30 days of protocol initiation.
* Known hypersensitivity/allergic reaction to any of the components of the therapeutic agents in mGAP or NALIRIFOX.
* Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, and participate in the study or who is likely to interfere with the interpretation of the results.
* Unwilling or unable to comply with study procedures and/or study visits.
* Uncontrolled, active infection
* Histologic diagnosis other than adenocarcinoma.
* Medical co-morbidities, that preclude major abdominal surgery

Where it's running

• Hollings Cancer Center at Medical University of South Carolina
  Charleston, South Carolina, United States Recruiting
• Medical University of South Carolina Hollings Cancer Center
  Charleston, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Albert Lockhart, MD — Medical University of South Carolina
• Study coordinator: HCC Clinical Trials Office, MD
• Email: hcc-clinical-trials@musc.edu
• Phone: 843-792-9321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Adding panitumumab to chemotherapy for unresectable or metastatic KRAS wild-type pancreatic cancer

  This trial will test whether giving the antibody panitumumab along with standard chemotherapy helps people with unresectable, locally advanced, or metastatic KRAS wild-type pancreatic cancer live longer.

  Recruiting at 272 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 273 other locations · NCT06998940

• Setidegrasib with mFOLFIRINOX or NALIRIFOX for KRAS G12D metastatic pancreatic cancer

  This trial tests whether adding setidegrasib to mFOLFIRINOX or NALIRIFOX helps people with metastatic pancreatic cancer who have a KRAS G12D mutation.

  Recruiting at 104 sites Phase 3 Astellas Pharma Inc · Gilbert, Arizona and 103 other locations · NCT07409272

• Surgery after tumor-shrinking treatment for locally advanced pancreatic cancer

  This project will test whether doing surgery after at least four months of chemotherapy helps people with locally advanced pancreatic cancer that was initially considered not removable live longer and feel better.

  Recruiting Azienda Ospedaliera di Padova · Padova · NCT07241663

• BMS-986340 with nivolumab plus gemcitabine and nab-paclitaxel for advanced or recurrent pancreatic adenocarcinoma

  This trial tests whether adding the antibody BMS-986340 to nivolumab together with gemcitabine and nab-paclitaxel helps people with metastatic or recurrent pancreatic adenocarcinoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07226856

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.